Cargando…

Immune Checkpoint Inhibitors in Mismatch Repair Proficient/Microsatellite Stable Metastatic Colorectal Cancer Patients: Insights from the AtezoTRIBE and MAYA Trials

SIMPLE SUMMARY: Immune-checkpoint inhibitors (ICI) show modest activity and efficacy in microsatellite stable (MSS) metastatic colorectal cancer (mCRC) patients harbouring a proficient mismatch repair system (pMMR). Recently, two phase 2 trials -AtezoTRIBE and MAYA- have challenged this dogma throug...

Descripción completa

Detalles Bibliográficos
Autores principales:	Germani, Marco Maria, Moretto, Roberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750658/ https://www.ncbi.nlm.nih.gov/pubmed/35008215 http://dx.doi.org/10.3390/cancers14010052

Ejemplares similares

AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer
por: Antoniotti, Carlotta, et al.
Publicado: (2020)

Early radiologic signal of responsiveness to immune checkpoint blockade in microsatellite-stable/mismatch repair-proficient metastatic colorectal cancer
por: Meltzer, Sebastian, et al.
Publicado: (2022)

Immunocheckpoint Inhibitors in Microsatellite-Stable or Proficient Mismatch Repair Metastatic Colorectal Cancer: Are We Entering a New Era?
por: Matteucci, Laura, et al.
Publicado: (2023)

Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study
por: Moretto, Roberto, et al.
Publicado: (2023)

Immune Checkpoint Inhibition in Metastatic Colorectal Cancer Harboring Microsatellite Instability or Mismatch Repair Deficiency
por: Cohen, Romain, et al.
Publicado: (2021)

Immuno-Contexture and Immune Checkpoint Molecule Expression in Mismatch Repair Proficient Colorectal Carcinoma
por: Giacomelli, Mauro, et al.
Publicado: (2023)

Immunotherapy combined with local therapy in the late-line treatment of repair-proficient (pMMR)/microsatellite stable (MSS) metastatic colorectal cancer
por: Ding, Yuwei, et al.
Publicado: (2023)

Microsatellite stability and mismatch repair proficiency in nasopharyngeal carcinoma may not predict programmed death-1 blockade resistance
por: Liao, Xiyi, et al.
Publicado: (2017)

Immunoscore in mismatch repair‐proficient and ‐deficient colon cancer
por: Wirta, Erkki‐Ville, et al.
Publicado: (2017)

Estimating probability of germline mismatch repair mutations in colorectal cancer patients with microsatellite stable tumors
por: Everett, Jessica N, et al.
Publicado: (2011)

Dendritic cell paucity in mismatch repair–proficient colorectal cancer liver metastases limits immune checkpoint blockade efficacy
por: Ho, William W., et al.
Publicado: (2021)

Efficacy and safety of immune checkpoint inhibitors in Proficient Mismatch Repair (pMMR)/ Non-Microsatellite Instability-High (non-MSI-H) metastatic colorectal cancer: a study based on 39 cohorts incorporating 1723 patients
por: Wu, Qing, et al.
Publicado: (2023)

Case report: mismatch repair proficiency and microsatellite stability in gastric cancer may not predict programmed death-1 blockade resistance
por: Chen, Kuo-Hsing, et al.
Publicado: (2016)

Survival of Patients with Deficient Mismatch Repair Versus Proficient Mismatch Repair Metastatic Colorectal Cancer Receiving Curative-Intent Local Treatment of Metastases in a Nationwide Cohort
por: Zwart, Koen, et al.
Publicado: (2023)

BRD4 inhibition impairs DNA mismatch repair, induces mismatch repair mutation signatures and creates therapeutic vulnerability to immune checkpoint blockade in MMR-proficient tumors
por: Fu, Yu, et al.
Publicado: (2023)

Robust Glycogene-Based Prognostic Signature for Proficient Mismatch Repair Colorectal Adenocarcinoma
por: Li, Yixi, et al.
Publicado: (2021)

Role of Mismatch Repair Deficiency Status and Microsatellite Instability in Relation to the Expression of Immune Checkpoint Proteins in Colorectal Cancer
por: Sharma, Antariksha, et al.
Publicado: (2023)

Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite Instability
por: Borelli, Beatrice, et al.
Publicado: (2022)

Efficacy of Immune Checkpoint Inhibitors in Patients with Mismatch Repair-Deficient or Microsatellite Instability-High Metastatic Colorectal Cancer: Analysis of Three Phase-II Trials
por: Cancanelli, Luca, et al.
Publicado: (2021)

Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden
por: Quintanilha, Julia C. F., et al.
Publicado: (2023)

Evaluation of tyrosine kinase inhibitors combined with antiprogrammed cell death protein 1 antibody in tyrosine kinase inhibitor-responsive patients with microsatellite stable/proficient mismatch repair metastatic colorectal adenocarcinoma: protocol for open-label, single-arm trial
por: Dong, Qian, et al.
Publicado: (2022)

Current Landscape and Potential Challenges of Immune Checkpoint Inhibitors in Microsatellite Stable Metastatic Colorectal Carcinoma
por: San-Román-Gil, María, et al.
Publicado: (2023)

ASO Author Reflections: Clinical Outcome After Upfront Curative-Intent Local Treatment of Metastases in Patient with Deficient Mismatch Repair Versus Proficient Mismatch Repair Metastatic Colorectal Cancer
por: Zwart, Koen, et al.
Publicado: (2023)

Photodynamic therapy of DNA mismatch repair-deficient and -proficient tumour cells
por: Schwarz, V A, et al.
Publicado: (2002)

Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO
por: Rossini, Daniele, et al.
Publicado: (2020)

Role of the VEGF ligand to receptor ratio in the progression of mismatch repair-proficient colorectal cancer
por: Eppenberger, Manuela, et al.
Publicado: (2010)

Characterisation of the oxysterol metabolising enzyme pathway in mismatch repair proficient and deficient colorectal cancer
por: Swan, Rebecca, et al.
Publicado: (2016)

The Emerging Role of Checkpoint Inhibition in Microsatellite Stable Colorectal Cancer
por: Hermel, David J., et al.
Publicado: (2019)

Advances in immune therapies for the treatment of microsatellite instability-high/deficient mismatch repair metastatic colorectal cancer (Review)
por: Choucair, Khalil, et al.
Publicado: (2021)

Quantitative assessment of tumor-infiltrating lymphocytes in mismatch repair proficient colon cancer
por: Jimenez-Rodriguez, Rosa M., et al.
Publicado: (2020)

Risk for Hereditary Neoplastic Syndromes in Women with Mismatch Repair-Proficient Endometrial Cancer
por: dos Santos, Jennifer Thalita Targino, et al.
Publicado: (2023)

Comparison of immunological characteristics between paired mismatch repair-proficient and -deficient colorectal cancer patients
por: Liu, Shou-Sheng, et al.
Publicado: (2018)

Distinct microbes, metabolites, and ecologies define the microbiome in deficient and proficient mismatch repair colorectal cancers
por: Hale, Vanessa L., et al.
Publicado: (2018)

The Impact of Tumor Cell-Intrinsic Expression of Cyclic GMP-AMP Synthase (cGAS)-Stimulator of Interferon Genes (STING) on the Infiltration of CD8(+) T Cells and Clinical Outcomes in Mismatch Repair Proficient/Microsatellite Stable Colorectal Cancer
por: Nakajima, Shotaro, et al.
Publicado: (2023)

Microsatellite diversity among the primitive tribes of India
por: Mukherjee, Malay B., et al.
Publicado: (2009)

Mismatch Repair/Microsatellite Instability Testing Practices among US Physicians Treating Patients with Advanced/Metastatic Colorectal Cancer
por: Eriksson, Jennifer, et al.
Publicado: (2019)

Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers
por: Amodio, Vito, et al.
Publicado: (2021)

Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer
por: Kasi, Pashtoon Murtaza, et al.
Publicado: (2023)

IGSF6 is a novel biomarker to evaluate immune infiltration in mismatch repair-proficient colorectal cancer
por: Rong, Yu-ming, et al.
Publicado: (2023)

Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer
por: Konstantinopoulos, Panagiotis A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6879khhta45e0fjprdhb0m38ql